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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not, “Is 
Afrin (Oxymetazoline) a safe and effective drug in normal, healthy adults with reference to nasal 
congestion and the nasal response?”   
 
STUDY DESIGN: Review of three English language primary studies published in 1997, 1999, 
2003. 
 
DATA SOURCES:  Randomized, controlled studies (double-blind, placebo-controlled) testing 
the efficacy and safeness of Afrin in comparison to a placebo group, were found using the 
PubMed database.   
 
OUTCOMES MEASURED: Nasal patency, congestion, degree of nasal blockage, and symptoms 
(quantity, consistency, color of nasal secretions, turbinate size/color) were measured through 
patient diary card symptom scores, visual analogue scales, and clinical nasal visual 
examinations.    
 
RESULTS: The Morris et al and Watanabe et al studies found that the subjective measurements 
and nasal examinations did not show clinically significant signs of rhinitis or differences 
between treatment groups after using Afrin.  A clinically significant decongestant effect of Afrin 
was noted at each visit in all three RCT’s.  Bickford et al reports that symptoms of congestion 
decreased significantly after using Afrin but not after using the placebo.  Morris et al and 
Watanabe et al found no signs of increased tolerance to Afrin, but evidence of rebound nasal 
congestion was reported after 3 days of Afrin treatment in the Morris study and no significant 
rebound nasal congestion was discovered by Watanabe et al after 4 weeks treatment.   
  
CONCLUSIONS:  All three RCT’s showed that Afrin is effective in treating nasal congestion in 
normal, healthy adults.  After subjects were treated with various doses of Afrin nasal spray, no 
clinically significant nasal congestion was found in any of the treatment groups.  Morris et al and 
Watanabe et al found that there was no tolerance to the medication after using repeated doses.  
However, Morris et al found rebound nasal congestion after 3 days of use, whereas Watanabe et 
al found no rebound congestion after using various doses of Afrin for 4 weeks.  Further research 
is needed to determine the appropriate length of treatment and possible side effects (rebound 
congestion) of Afrin.              
 
KEY WORDS: Afrin; Oxymetazoline; Nasal Congestion; Adults   
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INTRODUCTION 
 
 Nasal congestion is an extremely common problem and complaint, affecting the majority 
of the population including each gender, race and age group across the world.  Due to the 
numerous etiologies of nasal congestion and acute rhinitis, there are a myriad of treatment 
options to help ameliorate this problem.  Therefore, treatment decisions can become quite 
difficult for both the consumer and provider.  It is important to know which drugs not only 
provide the best treatment and relief, but those that have minimal side effects and maximum 
safety.  This systematic review analyzes three placebo-controlled, double-blind, randomized 
controlled trials in normal, healthy men and women, age 16 and above, in order to determine the 
efficacy and safeness of Afrin (Oxymetazoline) with reference to nasal congestion and the nasal 
response.   
 The prevalence of nasal congestion is increasing worldwide, now including more than 
10-40% of the total population.1  In 2003, a Gallup poll found that >50% of Americans are 
suffering from nasal congestion and will self medicate to relieve their symptoms.1  Allergic 
rhinitis has been identified as the most common cause of nasal congestion, affecting at least 40 
million (>20%) of Americans today.2  Around 1 in 7 adults (14%), >18 years of age, have been 
diagnosed with allergies, with more than 60% of those patients reporting daily nasal congestion.1    
“The apparent increase in the prevalence of allergic rhinitis in studies worldwide highlights the 
need for more effective treatment options for allergic rhinitis…congestion in particular.”1   
 The economic impact of nasal congestion alone is currently unknown.  Research focuses 
primarily on the causes, most frequently allergic rhinitis and rhinosinusitis, which have nasal 
congestion as their most common symptom.1  In 2011, $5.3 billion/year was estimated as the 
total direct and indirect cost of allergic rhinitis alone.2  However, there are several other co-
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morbidities, such as asthma, that encompass nasal congestion as a symptom as well.  The 
increasing prevalence also increases the number of healthcare visits per year.  In 2005, there 
were more than 13 million office visits in which the patient presented with nasal congestion as a 
chief complaint.1  In 2006, allergic rhinitis alone accounted for >12 million office visits per 
year.1  These staggering numbers help to recognize the increased need for an effective and safe 
fix. 
   Currently, many treatment options are available; however, both patients and providers 
remain unsure as to which products are best.  Current guidelines exist regarding the length of 
treatment for nasal congestion with reference to rebound complications, but the precise 
mechanism of rebound congestion, and other complications is still unknown.2  Different drugs 
and the components within each treatment can lead to various side effects when used for 
different periods of time and further research must still be conducted to determine which drugs 
are most appropriate.2       
 The most commonly used treatments for nasal congestion include oral antihistamines, 
decongestants, or both as needed.2  Depending on the source of the congestion, different 
medications within certain classes are used.  For example, an intranasal steroid spray is 
frequently used in cases of chronic congestion.2  Other treatment options include: 2nd generation 
antihistamines, intranasal antihistamine sprays, leukotriene receptor agonists, intranasal 
Cromolyn, intranasal anticholinergic sprays, short courses of corticosteroids, and first generation 
antihistamines.2  Afrin falls within the nasal decongestant class.  It works by narrowing the blood 
vessels within the nasal canal.2  
 The widespread usage of nasal decongestants like Afrin, has led to increasing concerns of 
abuse, rebound complications such as nasal congestion, tachyphylaxis, and nasal mucosa 
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swelling, tolerance, efficacy and safeness.3  The amount of time remains unclear as to how long a 
nasal decongestant can be used for, and the correct dosage prior to developing undesirable 
effects.3  Afrin is compared to placebos in various dosages over different periods of time in order 
to determine its safety and efficacy, with reference to nasal congestion and the nasal response. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not, “Is Afrin 
(Oxymetazoline) a safe and effective drug in normal, healthy adults with reference to nasal 
congestion and the nasal response?” Recent studies have shown that Afrin is effective in treating 
acute nasal congestion, but it remains unclear as to the correlation between prolonged use of the 
drug and rebound complications.   
METHODS 
 Certain criteria were used to select similar studies in order to obtain more specific, 
accurate results.  Each study selected focused on a population consisting of normal, healthy adult 
men and women 16 years of age or older.  All three articles concentrated upon the intervention 
Afrin (Oxymetazoline), a topical decongestant nasal spray, and compared the effects of Afrin at 
varying dosages to the effects of a placebo.  Morris et al3 is a double-blind, placebo- controlled 
randomized controlled trial that studied 7 days of Afrin (0.05%) nasal spray treatment in subjects 
that received either daily Afrin (0.05%), intermittent Afrin (0.05%) morning doses on days 1, 3, 
and 7 with all other doses placebo, or daily placebo doses for comparison.  Bickford et al4 is a 
double-blind, placebo-controlled, randomized controlled trial and crossover study that focused 
on the administration of Afrin nasal spray 0.5 mg ml-1 (0.9 mg to each nostril) in comparison to a 
placebo nasal spray made of saline solution 0.9% to each nostril.  Nasal patency measurements 
were made up to an hour prior to medication delivery and up to 120 minutes post delivery. 4  The 
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crossover was measured 7-21 days later.4  Watanabe et al5 is a double-blind, placebo-controlled 
randomized controlled trial that used 0.05% Afrin nasal spray, 2 sprays (0.1 ml/spray) to each 
nostril 3 times daily and compared it to a matched placebo nasal spray over a 4 week period.  In 
this study, both the Afrin and the placebo nasal spray contained the chemical benzalkonium 
chloride 0.1%.5  Each study measured nasal patency, nasal congestion, degree of nasal blockage, 
and symptoms including: quantity, consistency, color of nasal secretions, and turbinate size and 
color.3,4,5    
 In order to successfully locate articles pertaining to Afrin’s efficacy and safeness with 
similar subject populations, a detailed and refined search was conducted using the key words, 
“Afrin,” “Oxymetazoline,” “Nasal congestion,” and “Adults.”  Several databases were reviewed 
including OVID, Medline, Cochrane and PubMed; however, the articles analyzed in this paper 
were all located on the PubMed database.  All selected articles are written in the English 
language and published in peer-reviewed journals.  To narrow down the selection, each article 
was chosen based on relevance and patient-oriented evidence that matters (POEMS).  Inclusion 
criteria for article selection included: randomized controlled trials published after 1996, POEMS, 
healthy adult patients >16 years of age, and minimal nasal airway resistance at baseline with 
normal nasal anatomy.  Exclusion criteria includes: subjects with a past medical history of 
significant medical disease, seasonal allergies, nasal deformity/deviation, those who have taken 
recent medications such as antihistamines or decongestants, those who have had a recent URI or 
cold, and smokers. 3,4,5  The statistics reported are: p-values with a significant result <0.05, 
change in mean from baseline, mean +/- SD3; CI interval, ANOVA, CV4; and RRR, ARR, 
NNT5.   
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Table 1: Demographics & characteristics of included studies for analysis of Afrin with reference 
to nasal congestion and the nasal response: 
Study Type # Pts Age Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Morris3,  
1997 
RCT, double 
blind, 
placebo 
controlled 
50 18-59 50 healthy 
subject 
volunteers 
between 18-
59, male or 
female 
NAR on day 1 >0.3 
Pa/cm3/s, hx of 
alcohol/ drug abuse; 
hx of any significant 
disease; rhinitis; 
deviated nasal 
septum, polyps, etc; 
not on current 
medications 
affecting nasal 
congestion; smoker; 
pregnant 
N/A 7 days tx with 
Oxymetazoline 
(0/05% w/v) nasal 
spray; randomized 
to receive either 
daily(0.05%) or 
intermittent (0.05% 
with morning doses 
on days 1,3,7 and 
all other doses 
placebo) 
Bickford4, 
1999 
RCT, double 
blind, 
placebo 
controlled 
crossover 
study 
20 18+ 
mean 
27.3  
20 healthy 
adult 
volunteers, 
male or 
female; 
minimal 
baseline 
NAR of at 
least 0.15 
Pa/s/cm-3 
All subjects free of 
URI and no 
evidence of 
pharyngeal 
erythema, anatomic 
nasal 
obstruction/deformit
y; no sx of nasal 
congestion; could 
not have taken meds 
which may have 
influenced nasal 
congestion or 
interacted with 
Afrin 
0 Nasal Spray 
Oxymetazoline 0.5 
mg ml -1(0.9 mg to 
each nostril) 
compared to nasal 
spray placebo 
(saline solution 
0.9%) to each 
nostril 
Watanabe5, 
2003 
RCT, double 
blind, 
placebo 
controlled 
30 16-60 Negative hx 
of seasonal/ 
perennial 
nasal sx 
other than 
common 
cold, non-
smokers, 
normal lung 
function, 
normal 
nasal 
anatomy  
Current smokers, 
taking concurrent 
medication, hx of 
use of topical or 
systemic nasal 
vasoconstrictors in 
last 6 months, hx of 
URI in last 4 wks, 
pmh of htn, CVD, or 
other significant 
medical problems 
0 0.05% 
Oxymetazoline 
Nasal Spray: 2 
sprays (0.1 
ml/spray) to each 
nostril 3x daily 
over extended 
period of 4 weeks 
in comparison to 
placebo nasal spray 
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OUTCOMES MEASURED 
 Both the patient and clinician measured outcomes in order to determine symptoms of 
nasal congestion, blockage or patency.  Morris et al3 utilized subjective scaling of nasal patency 
through a visual analogue scale (VAS) and through a clinical examination by a physician.  
Bickford et al4 also measured the outcomes through a 100-mm visual analogue scale with 
descriptors ranging from “nose completely clear,” to “nose completely blocked,” representing 
values of 0 and 100 mm respectively.  Watanabe et al5 had subjects complete a diary card of 
nasal symptoms and undergo a clinical examination.  The card included: nasal blocking (scale 0-
4), 0= no symptoms, 1=mild blockage, 2= moderate blockage, 3=severe blockage, 4= complete 
nasal blockage.5       
RESULTS 
 The results pertaining to the primary outcome were presented as continuous data in all 
three studies.  The continuous data presented in both the Morris et al 3  and Bickford et al4  studies 
was unable to be changed into dichotomous form; however, the data presented in Watanabe et al5 
could be converted.     
 The Morris et al 3 RCT assessed the nasal response in 50 subjects after 7 days of Afrin 
regimes, by measuring nasal airway resistance (NAR) subjectively through a visual analogue 
scale (VAS) and clinical examination.  The VAS and NAR subjective results were similar 
throughout the study with no separation between the treatment groups.  Day 1 results (Table 2) 
illustrated a significant decongestant effect (p < 0.05) which occurred 30 minutes after drug 
administration and continued for up to 6 hours in both the daily and intermittent groups.    
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Table 2: Mean NAR change in baseline before and after treatment on Day 1: 
 Mean NAR Pre Tx Mean NAR Post Tx 
Daily Afrin Tx Group 0.23 + 0.05 Pa/cm3 /s 0.15 + 0.04 Pa/cm3 /s 
Intermittent Afrin Tx Group 0.22 + 0.07 Pa/cm3/s 0.15 + 0.04 Pa/cm3 /s 
Placebo Group 0.26 + 0.09 Pa/cm3  /s 0.39 + 0.35 Pa/cm 3 /s 
However, the change in baseline of the mean NAR for the placebo group increased significantly 
(p<0.05). 3   The change from baseline was higher on Day 3 and 7 than on Day 1 for the daily 
and intermittent groups.  Oxymetazoline remained effective at reducing the NAR throughout all 
7 days, showing its significant decongestant effect without the development of a drug tolerance. 3   
Table 3: Mean Baseline NAR on Day 1 and Day 3 for Daily and Intermittent Treatment Groups: 
 Daily: Baseline NAR Intermittent: Baseline NAR 
Day 1 0.23 + 0.05 Pa/cm3/s 0.22 + 0.07 Pa/cm3/s 
Day 3 0.38 + 0.23 Pa/cm3/s 0.31 + 0.15 Pa/cm3/s 
The significant change in mean baseline (p<0.05) in both the daily and intermittent groups 
indicates rebound congestion.  The trend continued on to Day 7 but it was not statistically 
significant.  The NAR baseline in placebo group also increased; however, it did not reach 
statistical significance as well.   After treatment was completed, the intermittent group was the 
only group with significantly higher NAR on days 8 and 9 in comparison to day 1 (p <0.05).3   
 Bickford et al 4, a crossover trial, assessed symptoms of congestion through a visual 
analogue scale (CON, range 0-100) and the results were illustrated by the AUC showing a 
change from baseline value.  When referring to the efficacy variables, the baseline values were 
similar on both days of the crossover studies.  The nasal airway resistance (NAR) and subjective 
CON values indicating symptom scores, remained unchanged after the placebo, but fell 
significantly after the Oxymetazoline at all times 2 hours post dosing.  Both the NAR AUC and 
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the CON AUC showed significant differences between the Oxymetazoline and placebo groups, 
P< 0.001 and P= 0.012 respectively.4 
 Watanabe et al5 is a randomized double-blind, placebo-controlled continuous study in 
which its data is capable of being converted into dichotomous format (see Table 4).  The 
treatment effects were analyzed using the Wilcoxon rank test.  At baseline, nasal patency 
between the treatment groups was not statistically different and groups were matched for gender, 
baseline lung function and atopic status.  After subjective diary symptom scores and clinical 
exams were completed post Oxymetazoline challenge, the results did not show a significant 
increase in subjective nasal blockage after 4 weeks of usage and 6 weeks of total monitoring for 
the Oxymetazoline or placebo groups.  There was also a highly significant decongestant effect 
after each Oxymetazoline treatment.  However, the subject diary symptom scores were unable to 
be analyzed numerically because the majority of the results showed a 0, indicating “no blockage” 
for both treatment groups at all points throughout the study.  A possible trend in the placebo 
group was developing, showing mild and occasionally moderate nasal blockage but it was not 
significantly different between the groups.  The clinical examination did not find significant 
changes in the nasal mucosa appearance, significant bleeding, or findings associated with rhinitis 
medicamentosa in either group. 5  Table 4 uses the evening measurements at the end of the 4 
week treatment period, to analyze the outcome of nasal congestion for prevention.  
 Table 4: Analysis of RRR and NNT for Prevention in the Watanabe et al5 study: 
Control Event Rate 
(CER) 
Experimental 
Event Rate (EER) 
Relative Risk 
Reduction (RRR) 
Absolute Risk 
Reduction (ARR) 
Number Needed to 
Treat (NNT) 
67% 93% 38.8% 26% 4 
 
The NNT illustrates that for every 4 patients that are treated, 1 patient will be symptom free, 
therefore preventing a negative outcome such as worsening of symptoms or complications, when 
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compared to a placebo at 4 weeks.  However, negative outcomes were not significant in this 
study.    
 Due to the limited adverse effects of Afrin and the lack of complications within all 3 
studies, each study had a 100% compliance rate.  On clinical exam, changes in the nasal mucosa 
were not found in any of the studies, and trends of rebound congestion were noted to be the only 
adverse effect found when using Afrin in healthy, normal adults.3,4,5           
DISCUSSION 
 Afrin is one of the most commonly used medications to treat nasal congestion; however, 
the general population associates prolonged use of this medication with rebound effects and 
complications.  According to Morris et al3, prior studies have focussed on weeks, months or 
years of decongestant use and little research has been published on Afrin use for shorter periods 
of time.  In 1985, the FDA recommended that decongestant products such as Afrin should be 
used for a maximum of 3 days and stated that these medications produce rebound congestion 
within hours of use.3  However, their recommendation centered upon long term Afrin use in 
studies conducted more than 30 years ago.  Current literature focussing upon short term 
decongestant use and its possible rebound effects remains unclear. 
 According to PubMedHealth6, recent guidelines suggest using Afrin nasal spray every 
10-12 hours as needed but no more than twice in a 24 hour period.  Users are instructed to use 
the spray for no more than 3 days consecutively and a warning is given that if the drug is used 
for longer than the recommended period of time, the congestion can worsen, improve, or come 
back.  Possible side effects include: burning, stinging, increased nasal discharge, dryness inside 
the nose, sneezing, nervousness, nausea, dizziness, headache, difficulty falling asleep or staying 
asleep, fast heartbeat or slow heartbeat.6   
  Rubinstein, Afrin Safety & Effectiveness, 10  
  
 
 When referring to efficacy, Morris et al3 showed that Afrin was just as effective in 
reducing the NAR on day 1 as on day 7 and Watanabe et al5 found no significant increases in 
subjective nasal blockage after 4 weeks of treatment and for 2 weeks after discontinuation of the 
drug.  All three studies found a highly significant decongestant effect, therefore indicating that 
not only is Afrin effective in eliminating nasal congestion, but Afrin does not cause a drug 
tolerance to develop after continual doses.   
 The safety of this drug remains unclear because some evidence, as seen in Morris et al3, 
shows that Afrin may cause rebound congestion after 3 days of treatment, but Watanabe et al5 
found no evidence of rebound congestion or other side effects after 4 weeks of continuous 
dosing.  In the Morris et al3 study, the baseline NAR on day 3 was significantly greater than day 
1 in both the daily and intermittent groups, but the baseline NAR differences between the 
treatment and placebo groups did not reach significance on any of the days.  However, the 
rebound congestion on day 3 cannot be attributed to Afrin use alone because the baseline NAR 
increased over the course of the study in both the treatment and placebo groups. It is possible that 
the benzalkonium chloride in the placebo contributed to the rebound congestion by acting as a 
nasal irritant and reducing mucociliary clearance.3 
 While Morris et al3 and Watanabe et al5 recruited volunteers without a baseline nasal 
airway resistance, the Bickford et al4 study used participants with a minimal NAR baseline, but 
still within the normal range, to increase the ability of detecting a significant decrease in NAR.  
In the Bickford et al4 study, Afrin showed a significant decongestant effect in the subjective 
results that was further verified by parallel results of the objective measurements.4    
 Possible limitations to help explain variability within results include small sample sizes, 
the use of irritants and various substances in some of the placebo sprays, and subjective scaling.  
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It is possible that spraying a placebo into the nasal canal can lead to rebound congestion and 
further studies are needed to determine if the substances in the vehicle spray are responsible for 
causing rebound side effects.  Subjective scaling is also not the most accurate way to detect 
congestion because perceptions of symptom severity can differ from person to person and 
symptoms can be affected by sensory changes as well as changes in NAR.  
CONCLUSION 
 All three randomized controlled trials demonstrated that Afrin is an effective treatment in 
normal healthy adults with reference to nasal congestion and the nasal response.  After subjects 
were treated with various doses of Afrin over different periods of time, no evidence of significant 
nasal congestion was found after continually using the drug, also showing that a tolerance to the 
drug does not develop.  However, there was conflicting evidence regarding drug safety and 
appropriate length of treatment prior to developing side effects.  Morris et al3 found rebound 
congestion after 3 days of Afrin use, whereas Watanabe et al5 found no evidence of rebound 
congestion after 4 weeks of use.    
 Future studies are warranted to determine the appropriate length of treatment, when side 
effects occur, and if they even occur at all.  Current studies often use placebos that contain 
substances like benzalkonium chloride, which can lead to nasal congestion, possibly impacting 
the validity of the results.  Research is indicated to determine if these substances, which can be 
found in both the placebo and Afrin nasal sprays, are causing rebound congestion.  It is essential 
that appropriate length of treatment and adverse side effects be fully understood to help those 
who are suffering from nasal congestion feel that their symptoms are being treated adequately.             
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